

Atrial fibrillation in a couple: a case report

Erica Delsignore¹, M Cristina Bertoncelli¹, Tiziana Ciarambino², Cecilia Politi²

1. SC Medicina Interna, Ospedale S. Andrea, Vercelli; 2. UOC Medicina Interna, Ospedale F. Veneziale, Isernia, Italy. —
Received 14 January 2016; accepted 26 February 2016.

Summary. We present a case report confirming previous findings of epidemiological studies: not only does atrial fibrillation (AF) show different features between genders, related to biological differences, in terms of prevalence, clinic characteristics and complications, but there is also possibility for people of different gender to receive different treatments.

Key words: atrial fibrillation, gender, anticoagulant oral therapy.

Un caso clinico di fibrillazione atriale (di coppia)

Riassunto. Presentiamo un caso che conferma quanto già segnalato dagli studi epidemiologici: non solo la fibrillazione atriale può avere caratteristiche diverse nei due generi, legate a differenze biologiche, in termini di prevalenza, caratteristiche cliniche e complicanze, ma esiste anche la possibilità che persone di diverso genere ricevano un differente trattamento farmacologico.

Parole chiave: fibrillazione atriale, genere, terapia anticoagulante orale.

Atrial fibrillation (AF), a common cardiac arrhythmia in Western countries and Japan, not only has a different prevalence between men and women¹, but, as reported in different studies, shows also sex-related difference in clinical and pharmacological treatment^{1,2}. There is often a tendency to believe that women are protected against cardio-vascular diseases, but this wrong cultural assumption comes from a possible difficult and/or delayed diagnosis because women may show more nuanced symptomatic features that differ from those of males. We have to consider that until a few years ago women were left out from trials and studies and that the conclusions were drawn from observations on men that are not necessarily applicable to women. Moreover, women tend to underestimate their symptoms, to be more hesitant to accept medical check-ups and drug prescriptions and in general to put the care of others before themselves.

Like other cardiac pathologies, some studies have found gender differences in AF treatment, showing that at times a most conservative approach is preferred for women, while other studies have highlighted a less frequent use of oral anticoagulant therapy (OAT).

Case report

We report two cases of patients with AF who received different diagnostic and therapeutic approach.

- Male, 83 years old, F.B., former smoker, with arterial hypertension, chronic kidney disease stage III-IV, dilated cardiomyopathy (EF 35-40%), AF with good response to cardioversion in 2003. After AF relapse, OAT was started with warfarin (in 2003 CHADS₂ = 3 and in 2009 CHA₂DS₂-VASc = 4, with a thromboembolic risk of 5.9%/year; HAS-BLED = 2), as recommended by guidelines, and heart rate control with betablockers. Two echocardiograms were performed in 2003 and in 2009, confirming damage to the anatomic structure of the heart damage and impaired cardiac function: he presented progressive left ventricular and atrial dilatation and mitral valve and tricuspid regurgitation. He died of cardiogenic shock in 2010, few months after his first admission to our Internal Medicine Unit.
- Female, 80 years old, L.R., clinical history of arterial hypertension, hyperthyroidism, previous NSAID-related gastric bleeding, obesity, persistent AF (CHA₂DS₂-VASc = 4, HAS-BLED = 3), diagnosed in the cardiology unit and treated with digoxin and ASA. At the time of the first medical examination at our unit, the echocardiogram was never performed.

We calculated stroke risk with CHADS₂ and CHA₂DS₂-VASc at the time of the first diagnosis of AF and at the time of hospitalization at our unit respectively, and HAS-BLED was also calculated (Table 1)^{3,5,7,8}.

Our patients had a similar risk of stroke and bleeding, but they were treated differently. Differences in HAS-BLED risk did not warrant the choice of antiplatelet therapy (with almost similar gastric bleeding rate) in the female patient, L.R.

It is amazing to note that our patients were married, had a similar age at time of diagnosis, lived in the same home, with the same primary care physician and were not conscious of having a similar yet differently treated disease, despite guidelines (Tables 2A, 2B)^{4,6-8}.

The woman accepted to start OAT only after her spouse's death, because before then she thought she did not have time to take care of her own health, but only that of her sick husband.

She started a novel oral anticoagulant a year ago, because she was in therapeutic range for insufficient time.

Conclusions

AF is the most common cardiac arrhythmia and independent risk factor for thromboembolism. Periodic guidelines are drawn up concerning rhythm/rate control and OAT in order to avoid thromboembolic stroke⁹.

Some studies have highlighted differences between genders in AF treatment and underutilization of OAT, despite the higher risk of stroke in women⁹, who also receive frequently more conservative treatment¹⁰. However, reports are not consistent.

Indeed, while the Canadian AF Registry quoted underutilization of OAT in 2001 (as many other reports), in 2013 the ATA-AF Study did not find differences and, in the same year, according to the FALP observational study, the male gender was negatively correlated to OAT^{11,12}.

According to the Euro Heart Survey on AF, women frequently were asymptomatic or had AF with atypical symptoms (dyspnea, chest pain, dizziness and fatigue),

while men displayed mainly typical symptoms (palpitations and syncope). In overall symptomatic cases, the authors did not find differences between genders, but the treatment was more conservative in asymptomatic women or women with atypical symptoms: they received electrical cardioversion less frequently (rate control was preferred), but no differences were found in OAT, in contrast with other studies^{10,13}. Women showed higher stroke risk, according to the Framingham and ATRIA studies that reported a high risk of thromboembolism if they did not receive OAT¹⁴.

Compared to the men, several potential mechanisms could contribute to prothrombotic milieu and thromboembolic risk in women, above all in menopause: estrogen decline-related upregulation in the production of inflammatory cytokines, alterations in the vascular and myocardial structure, impaired endothelial function, increased platelet aggregation and increase in arterial pressure, pulse pressure and pressure variability⁹.

Female gender should be an independent risk factor for thromboembolic stroke in AF and has been added to CHA₂DS₂-VASc by the Birmingham 2009 Schema and employed in the ESC 2010 guidelines^{8,15}. The NEMESIS Study has demonstrated that women have more severe

Table 1. Stroke risk assessment scores.

Stroke risk in patients with nonvalvular AF not treated with anticoagulation according to the CHADS ₂ Index			CHA ₂ DS ₂ -VASc score		HAS-BLED bleeding risk score		
CHADS ₂ risk criteria	Score		(a) Risk factors for stroke and thrombo-embolism in non-valvular AF		Letter	Clinical characteristic	Points awarded
Prior stroke or TIA	2		<i>'Major' risk factors</i>	<i>'Clinically relevant non-major' risk factors</i>	H	Hypertension	1
Age >75 y	1		Previous stroke, TIA, or systemic embolism	Heart failure or moderate to severe LV systolic dysfunction (e.g. LV EF ≤ 40%)	A	Abnormal renal and liver function (1 point each)	1 or 2
Hypertension	1		Age ≥75 years	Hypertension - Diabetes mellitus	S	Stroke	1
Diabetes mellitus	1			Female sex - Age 65–74 years	B	Bleeding	1
Heart failure	1			Vascular disease	L	Labile INRs	1
			(b) Risk factor-based approach expressed as a point based scoring system, with the acronym CHA ₂ DS ₂ -VASc (Note: maximum score is 9 since age may contribute 0, 1, or 2 points)		E	Elderly	1
Patients (N = 1733)	Adjusted stroke Rate (%/y) (95% CI)	CHADS₂ Score	Risk factor	Score	D	Drugs or alcohol (1 point each)	1 or 2
120	1.9 (1.2 to 3.0)	0	Congestive heart failure/LV dysfunction	1	Maximum 9 points		
463	2.8 (2.0 to 3.8)	1	Hypertension	1			
523	4.0 (3.1 to 5.1)	2	Age ≥ 75	2			
337	5.9 (4.6 to 7.3)	3	Diabetes mellitus	1			
220	8.5 (6.3 to 11.1)	4	Stroke/TIA/thrombo-embolism	2			
65	12.5 (8.2 to 17.5)	5	Vascular disease	1			
5	18.2 (10.5 to 27.4)	6	Age 65–74	1			
			Sex category (i.e. female sex)	1			
			Maximum score	9			
Modified from Gage BF, et al., JAMA 2001 ³ .			Modified from Camm JA, et al., Eur Heart J 2010 ⁸ .		Modified from Pisters R, Lane DA, Chest 2010 ⁵ .		

Table 2A. Antithrombotic therapy for patients with atrial fibrillation.

Recommendations for antithrombotic therapy in patients with AF	Antithrombotic therapy for patients with atrial fibrillation		
Class I	Risk category	Recommended therapy	
1. Administer antithrombotic therapy (oral anticoagulation or aspirin) to all patients with AF, except those with lone AF, to prevent thromboembolism. (Level of Evidence: A)	No risk factors	Aspirin, 81 to 325 mg daily	
2. Individualize the selection of the antithrombotic agent based on assessment of the absolute risks of stroke and bleeding and the relative risk and benefit for a particular patient. (Level of Evidence: A)	One moderate-risk factor	Aspirin, 81 to 325 mg daily, or warfarin (INR 2.0 to 3.0, target 2.5)	
3. Chronic oral anticoagulant therapy in a dose adjusted to achieve a target intensity of INR 2 to 3 in patients at high risk of stroke, unless contraindicated. (Level of Evidence: A)	Any high-risk factor or more than 1 moderate-risk factor	Warfarin (INR 2.0 to 3.0, target 2.5)*	
a. The need for anticoagulation should be reevaluated at regular intervals. (Level of Evidence: A)	Less validated or weaker risk factors	Moderate-risk factors	High-risk factors
b. INR should be determined at least weekly during the initiation of oral anticoagulation therapy and monthly when the patient is stable. (Level of Evidence: A)	Female gender	Age greater than or equal to 75 y	Previous stroke, TIA or embolism
4. Aspirin in a dose of 325 mg daily as an alternative in low-risk patients or in those with certain contraindications to oral anticoagulation. (Level of Evidence: A)	Age 65 to 74 y	Hypertension	Mitral stenosis
5. Oral anticoagulation for patients with AF who have rheumatic mitral valve disease or prosthetic heart valves (mechanical or tissue valves). (Level of Evidence: B)	Coronary artery disease	Heart failure	Prosthetic heart valve*
6. Base the target intensity of anticoagulation on the particular type of prosthesis, but it should not be less than INR 2 to 3. (Level of Evidence: B)	Thyrotoxicosis	LV ejection fraction 35% or less Diabetes mellitus	
	*If mechanical valve, target international normalized ratio (INR) greater than 2.5. INR indicates international normalized ratio; LV, left ventricular; and TIA, transient ischemic attack.		
Modified from Fuster V, Rydén LE, Circulation, 2001 ⁶ .	Modified from Fuster V, Rydén LE, Circulation, 2006 ⁷ .		

stroke symptoms and worse post-stroke impairment as opposed to men⁹.

In the ATRIA study, OAT was more protective for women with AF than among men with the same disease and they had a similar rate of major bleeding¹⁴, but several studies have shown suboptimal time in the therapeutic range compared to men⁹.

These results, as well as our case report, confirm gender differences, despite guidelines for the management of patients with AF and similar stroke risk.

This demonstrates an underutilization of OAT among women, which should be considered instead with greater attention in this gender, although inequality of treatment or therapeutic choices should not always be considered evidence of discrimination: at times, it may prove to be beneficial to women. For instance, rate control versus rhythm control could improve outcomes in female gender¹⁰.

Gender medicine, which applies the idea of the “difference between genders”, aims at providing the best treatment to everybody, whether men or women, and at achieving better gender-related therapy.

References

- Inoue H, Takashi Nozawa T. Sex-related differences in the risk factor profile and medication of patients with AF recruited in J-TRACE. *Circ J* 2010; 74: 650-4.
- Humphries K, Kerr CR. New-onset AF: sex differences in presentation, treatment and outcomes. *Circulation* 2001; 103: 2365-70.
- Gage BF, Waterman AD. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA* 2001; 285(22): 2864-70.
- Camm JA, Lip GYH. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. *Eur Heart J* 2012; 33: 2719-47.
- Pisters R, Lane DA. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. *Chest* 2010; 138 (5): 1093-100.
- Fuster V, Rydén LE. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary. *Circulation* 2001; 104: 2118-50.
- Fuster V, Rydén LE. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation. *Circulation* 2006; 114: e257-e354.

Table 2B. Approach to thromboembolism guidelines.

Approach to thromboprophylaxis in patients with AF			Recommendations for prevention of thromboembolism in non-valvular AF—general			
Risk category	CHA ₂ DS ₂ -VASc score	Recommended antithrombotic therapy	Recommendations	Class	Level	Ref
One 'major' risk factor or ≥2 'clinically relevant non-major' risk factors	≥ 2	OAC	Antithrombotic therapy to prevent thromboembolism is recommended for all patients with AF, except in those patients (both male and female) who are at low risk (aged <65 years and lone AF), or with contraindications.	I	A	21, 63, 104, 105, 106
			The choice of antithrombotic therapy should be based upon the absolute risks of stroke/thromboembolism and bleeding and the net clinical benefit for a given patient.	I	A	21, 63, 105
One 'clinically relevant non-major' risk factor	1	Either OAC or aspirin 75-325 mg daily. Preferred: OAC rather than aspirin.	The CHA ₂ DS ₂ -VASc score is recommended as a means of assessing stroke risk in non-valvular AF.	I	A	25, 36, 39
No risk factors	0	Either aspirin 75-325 mg daily or no antithrombotic therapy. Preferred: no antithrombotic therapy rather than aspirin.	In patients with a CHA ₂ DS ₂ -VASc score of 0 (i.e., aged <65 years with lone AF) who are at low risk, with none of the risk factors, no antithrombotic therapy is recommended.	I	B	21, 36, 82
			In patients with a CHA ₂ DS ₂ -VASc score ≥2, OAC therapy with: • adjusted-dose VKA (INR 2-3); or • a direct thrombin inhibitor (dabigatran); or • an oral factor Xa inhibitor (e.g. rivaroxaban, apixaban) ^d ... is recommended, unless contraindicated.	I	A	3, 4, 70, 82
AF = atrial fibrillation; CHA ₂ DS ₂ -VASc = cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65-74 and sex category (female); INR = international normalized ratio; OAC = oral anticoagulation, such as a vitamin K antagonist (VKA) adjusted to an intensity range of INR 2.0-3.0 (target 2.5).			In patients with a CHA ₂ DS ₂ -VASc score of 1, OAC therapy with: • adjusted-dose VKA (INR 2-3); or • a direct thrombin inhibitor (dabigatran); or • an oral factor Xa inhibitor (e.g. rivaroxaban, apixaban) ^d ... should be considered, based upon an assessment of the risk of bleeding complications and patient preferences.	Ila	A	33, 44
			Female patients who are aged <65 and have lone AF (but still have a CHA ₂ DS ₂ -VASc score of 1 by virtue of their gender) are low risk and no antithrombotic therapy should be considered.	Ila	B	33, 44
			When patients refuse the use of any OAC (whether VKAs or NOACs), antiplatelet therapy should be considered, using combination therapy with aspirin 75-100 mg plus clopidogrel 75 mg daily (where there is a low risk of bleeding) or—less effectively— aspirin 75-325 mg daily.	Ila	B	21, 26, 51, 109

Modified from Camm JA, Kirchhoff P, Eur Heart J, 2010⁸.

Modified from Camm JA, Lip GYH, Eur Heart J, 2012⁴.

- Camm JA, Kirchhoff P. Guidelines for the management of AF. The Task Force for the Management of AF of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-429.
- Cove CL; Albert CM. Female sex as an independent risk factor of stroke in AF. Thrombosis and Haemostasis 2013; 111: 385-91.
- Dagres N, Nieuwlaat R. Gender-related differences in presentation, treatment and outcome of patients with AF in Europe. JACC 2007; 49 (5): 572-7.
- Gussoni G, Di Pasquale G. Decision making for oral anticoagulation in AF: the ATA-AF Study. Eur J Intern Med 2013; 24 (4): 324-32.
- Campanini M, Frediani R. Real-world management of AF in Internal Medicine units: the FADOI "FALP" observational Study. J Cardiovasc Med 2013; 14: 26-34.
- Rienstra M, Van Veldhuisen DJ. Gender related differences in rhythm control treatment in persistent AF. Data of the Rate Control versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol 2005; 46: 1298-306.
- Fang MC, Singer DE. Gender differences in the risk of ischemic stroke and peripheral embolism in AF: The ATRIA Study. Circulation 2005; 112(12): 1687-91.
- Lip GYH, Nieuwlaa R. Refining clinical risk stratification for predicting stroke and thromboembolism in AF using a novel risk factor-based approach. The Euro Heart Survey on AF. Chest 2010; 137(2): 263-72.

Correspondence to:
Erica Delsignore
SC Medicina Interna,
Ospedale S. Andrea,
Vercelli, Italy
email eridelsi@tiscali.it